[HTML] cell.comFull View

[HTML][HTML] Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem Cell, 2020 - cell.com
Modeling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …
被引用次数：46 相关文章

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem Cell, 2020 - elibrary.ru
We thank J. Wu (Stanford Cardiovascular Institute, Stanford, CA) and the Stanford Biobank
for the healthy donor hiPSC lines. We also thank B. Conklin (Gladstone Institute of …

[引用][C] Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem Cell, 2020 - cir.nii.ac.jp
Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve
Therapeutic Potential and Reduce Toxicity | CiNii Research CiNii 国立情報学研究所 学術情報 …

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - paper.sciencenet.cn
Modeling cardiac disorders with human induced pluripotent stem cell (hiPSC)-
derivedcardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell stem …, 2020 - scholars.northwestern.edu
Modeling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity.

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem …, 2020 - europepmc.org
Modelling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …
[HTML] nih.gov

[HTML][HTML] Reengineering an antiarrhythmic drug using patient hiPSC-cardiomyocytes to improve therapeutic potential and reduce toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell stem …, 2020 - ncbi.nlm.nih.gov
Modelling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell stem …, 2020 - pubmed.ncbi.nlm.nih.gov
Modeling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …
[HTML] sciencedirect.com

[HTML][HTML] Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem Cell, 2020 - Elsevier
Modeling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity.

WL McKeithan, DAM Feyen, AAN Bruyneel… - Cell Stem …, 2020 - europepmc.org
Modelling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics …